December 1st, 2021
Diabetes Actual seeks to restore metabolic wellness through the use of proven therapies for reversing the ravages of diabetes by restoring insulin sensitivity. This is made possible through a partnership with the US-based company, Well Cell Global, as they deploy their FDA-approved, life-saving technology throughout the world.
Diabetes is the most expensive medical condition in the USA. Eventually, oral medications may not be enough to keep blood glucose levels normal. Diabetes Actual’s pulsatile insulin protocol restores insulin sensitivity to cells, helping to ensure that maximal energy is generated.
Diabetes Actual seeks to become a leading player in diabetes treatment globally through:
- Use of Physiologic Insulin Re-Sensitization (PIR) protocols; a novel approach based on the healthy innate reciprocal pulsatile release of insulin from the pancreas
- Providing a combination of additional clinical therapies alongside PIR protocols
- Creating licensing partnerships with regional distributors in the US, the Asia Pacific and GCC countries
With over 7,000 patients treated across 35 US clinics and 5 international treatment centers, their patented technology promotes cell health and organ revitalization, using a safe method that has evolved over the last 70 years of scientific progress.
I have been interested in diabetes for many years, both in the clinic and in the research lab. I am excited that now we have the tools to control insulin resistance and improve metabolic wellness in our patients. Since diabetes contributes to 6 of the top 10 causes of death including, heart diseases, stroke, cancer and Alzheimer’s, our approach should have far reaching effects on global health.– Dr. Mark Holterman, Founder of Diabetes Actual
Why an Initial License Offering?
This revolutionary technology needs to be available to all leading clinical providers. The ILO will open Diabetes Actual up to a broad network of supporters, who can help achieve our goal of treating as many diabetics as possible, as soon as possible.
Diabetes Actual banks revenue on the sale of territorial licenses, and for training local providers on the correct use of protocols.
For just $4 per license, ILO holders will receive 10% of Diabetes Actual’s revenue, divided evenly amongst all license holders.